Enhertu is a cancer drug driving NHS approvals as authorities weigh cost, access, and patient impact amid rising measles-health policy tensions.
Two unvaccinated residents in Pennsylvania have died from measles, triggering a public health debate. Governor Shapiro says vaccinations could have averted the deaths, while RFK Jr. questions the figures, fueling a political row that experts warn could hinder responses to the outbreak.
England has authorised Enhertu for routine NHS use for HER2‑low metastatic breast cancer, ensuring access for about 1,000 women annually. The decision follows a previous rejection over cost‑effectiveness and builds on a deal between NICE and drug makers AstraZeneca and Daiichi Sankyo. Scotland has already provided access since 2023.